Med Tech-related technology assessments from NICE in October 2025

Health Technology Evaluations (HTE) using the Early Value Assessment (EVA) approach are the new type of NICE guidance to provide rapid conditional recommendations on promising health technologies that have the potential to address unmet national needs. NICE evaluates the available evidence to determine if earlier patient and system access in the NHS is appropriate while further evidence is generated. 

In October 2025, NICE published one new EVA on Artificial Intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures and concluded that five technologies can be used in the NHS during the evidence-generation period as options to aid the opportunistic detection of vertebral fragility fractures: BriefCase-Triage, CINA-VCF Quantix, HealthOST, HealthVCF, and IB Lab FLAMINGO. These technologies can only be used according to their indications, as outlined in the instructions for use, and with consideration of the risk groups as recommended in NICE’s guideline on osteoporosis: assessing the risk of fragility fracture. More research is needed on Annalise Enterprise CXR/Annalise Container CXR, BoneView, and TechCare Spine. 

The National Institute for Health and Care Excellence (NICE) develops Interventional Procedures Guidance (IPG) for most novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from "for research only" to "for use with standard arrangements for clinical governance, consent, and audit." Recommendations are not binding, although they are followed by providers and commissioners. 

In October 2025, NICE released two new IPGs with the following recommendations: 

• Venoarterial extracorporeal membrane oxygenation (VA ECMO) for extracorporeal cardiopulmonary resuscitation (ECPR) can be considered as an option for managing in-hospital and out-of-hospital refractory cardiac arrest in adults with a shockable heart rhythm or reversible causes. More research is needed on the procedure for in-hospital and out-of-hospital refractory cardiac arrest in adults with a non-shockable heart rhythm or irreversible causes, before it can be used in the NHS.  

• Venoarterial extracorporeal membrane oxygenation (VA ECMO) for severe acute heart failure in adults can be used as an option as a bridge to recovery, a heart transplant, or an implanted left ventricular assist device (LVAD). When the potential for functional recovery is low or uncertain, and a heart transplant or implanted LVAD is unsuitable, the procedure should only be done as part of formal research. 

See the full details here. 

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.